Inflammatory responses occur within tissue microenvironments, with functional contributions from both haematopoietic (lymphocytic) cells and stromal cells (including macrophages and fibroblasts)
. These environments are complex -a compound of many different cell types at different stages of activation and differentiation. Traditional models of inflammatory disease highlight the role of antigen-specific lymphocyte responses and attempt to identify causative agents. However, recent studies have indicated the importance of tissue microenvironments and the innate immune response in perpetuating the inflammatory process. The prominent role of stromal cells in the generation and maintenance of these environments has begun to challenge the primacy of the lymphocyte in regulating chronic inflammatory processes. Sensible enquiries into factors regulating the persistence of inflammatory disease necessitate an understanding of the mechanisms regulating tissue homeostasis Inflammatory responses resulting from tissue injury or infection generally result in a beneficial, self-limiting, healing process. The classical macroscopic features of inflammation as described 2000 years ago by the Roman physician Celsus are rubor (redness), tumour (swelling), colour (heat) and dolour (pain), and reflect the underlying molecular and cellular processesspecifically the release of inflammatory mediators leading to localised recruitment of immune effector cells including neutrophils, monocytes and lymphocytes. These responses can be defined by three important characteristics: spatial distribution (site specificity), the identity of the inflammatory infiltrate (cell type and magnitude of influx), and temporal pattern (resolving versus persistent).
Contrasting acute and chronic inflammation
Defining acute and chronic inflammation might seem at first a straightforward process: acute inflammation presents as a short-lived process with complete resolution; by contrast, chronic inflammation presents as a long-lasting phenomenon associated with tissue hyperplasia and scarring. In practice, this segregation is not always clear. Gout, for example, can manifest clinically as a recurrent acute inflammatory lesion, lasting many years, whereas a tuberculin PPD (purified protein derivative of tuberculin) skin test is a chronic inflammatory process that resolves completely within a few weeks. A histological definition (acute inflammation characterised by a neutrophilic infiltrate; chronic inflammation characterised by a mainly mononuclear infiltrate), in combination with the clinical picture (resolution versus persistence), is probably more useful. Thus, inflammation can be seen as being either acute resolving, acute persistent, chronic resolving or chronic persistent.
Recruitment of leukocytes in inflammation is
characterised by an initial infiltration of neutrophils, present within an hour of the initiating stimulus. This phase is later replaced by a more sustained influx of mononuclear cells. One of the biological consequences of this perivascular accumulation of mononuclear cells is a change in the appearance of endothelial cells, which adopt a structure more like high endothelial venules, normally seen only in lymphoid tissue (Ref. 1) .
The molecular mechanisms controlling the switch from acute to chronic inflammation are becoming clearer. Cytokines and chemokinesproteins that participate in the conversation between immune and stromal cells -appear to play a particularly important role in this process. The chemokines form a superfamily of structurally related proteins subdivided into four subfamilies based on the arrangement of N-terminal cysteine residues (C, CC, CXC and CX 3 C families, respectively) (Table 1) (Ref. 2) . They act functionally to regulate tissue homeostasis and direct responses in both haematopoietic and stromal cells. A study monitoring the evolution of the leukocytic infiltrate in peritoneal inflammation (Ref. 3) has suggested that the interaction between interleukin 6 (IL-6) and its soluble receptor sIL-6R forms one of the major determinants of this temporal switch (Switch 1, Fig. 1 ). sIL-6R, produced by the infiltrating neutrophils, forms a complex with IL-6 and has the capacity to activate cells lacking expression of the cognate IL-6 receptor. This mechanism was shown to modulate CC and CXC chemokine expression directly. CXC chemokine expression induced by proinflammatory cytokines [IL-1 and tumour necrosis factor α (TNF-α)] was suppressed, whereas expression of the CC chemokine monocyte chemoattractant protein 1 (MCP-1; CCL2) was promoted. This chemokine shift suppresses further neutrophil recruitment and promotes a sustained mononuclear cell influx. Similarly, a study investigating the dynamics of and remodelling during inflammation. This article highlights recent insights into the factors regulating dynamic aspects of inflammation, focusing particularly on mononuclear cell infiltrates, their interactions with stromal cells in tissues and the relevance of these interactions to existing and possible future therapies. A key feature of current research has been a growing appreciation that disordered spatial and temporal interactions between infiltrating immune cells and resident stromal cells lie at the heart of disease persistence. GROβ  CXCR2  CXCL3  GROγ  CXCR2  CXCL4  PF4  Unknown  CXCL5  ENA-78  CXCR2  CXCL6  GCP-2  CXCR1, CXCR2  CXCL7  NAP-2  CXCR2  CXCL8 IL CCL1  I-309  CCR8  CCL2  MCP-1  CCR2  CCL3  MIP-1α  CCR1, CCR5  CCL3L1  LD78β  CCR1, CCR5  CCL4  MIP-1β  CCR5  CCL5  RANTES  CCR1, CCR3, CCR5  CCL6  Unknown  Unknown  CCL7  MCP3  CCR1, CCR2, CCR3  CCL8  MCP-2  CCR3, CCR5  CCL9/CCL10  Unknown  CCR1  CCL11  Eotaxin  CCR3  CCL12  Unknown  CCR2  CCL13  MCP-4  CCR2, CCR3  CCL14  HCC-1  CCR1, CCR5  CCL15  HCC-2/Lkn-1/MIP-1δ  CCR1, CCR  CCL16  HCC-4/LEC/LCC-1  CCR1, CCR2  CCL17  TARC  CCR4  CCL18  DC-CK1  Unknown  CCL19  MIP-3β/ELC  CCR7  CCL20  MIP-3α/LARC  CCR6  CCL21  6Ckine/SLC  CCR7  CCL22  MDC  CCR4  CCL23  MPIF-1/CKb8  CCR1  CCL24  Eotaxin-2  CCR3  CCL25  TECK  CCR9  CCL26  Eotaxin-3  CCR3  CCL27  CTACK  CCR10  CCL28  MEC  CCR3/CCR10 a The new nomenclature for human cytokines is detailed. Adapted from Ref. 95 .
CC chemokines
(for abbreviations see next page) Figure 1 . Two switches are involved in the development of persistent chronic inflammation. Both acute and chronic inflammation are characterised by an initial infiltration of neutrophils, followed by a more sustained influx of mononuclear cells. Neutrophils produce soluble IL-6 receptor (sIL-6R), which binds IL-6 produced by haematopoietic and stromal cells in the vicinity. The change from a neutrophilic to a mononuclear population requires a switch from CXC to CC chemokines (Switch 1), and this is regulated by IL-6. (RANTES, also produced by haematopoietic and stromal cells, is an alternative regulator of this switch, but the exact molecular mechanism involved remains unclear.) In this way, the nature of the inflammatory infiltrate is tailored to the inflammatory stimulus, such that the appropriate quantity and quality of leukocyte subsets are recruited. For the inflammatory infiltrate to resolve completely, a second switch must occur that allows infiltrating cells to die and be cleared (Switch 2). This becomes disordered, and persistent chronic inflammation results, when cytokines such as interferon β (IFN-β) and chemokines such as stromal-cell-derived factor 1 (SDF-1) are ectopically produced by stromal cells such as macrophages and fibroblasts (see also Fig. 3 ). As shown by the histological sections, persistent inflammation is associated with an abnormal increase in the number and distribution of leukocytes within the tissue, classically as a perivascular infiltrate (fig001cbb). Superimposed on this 'physiological' homing and recirculation of lymphocytes is the recruitment of immune cells to inflammatory sites -a key component of the inflammatory response. By contrast to the situation during leukocyte homing and recirculation, leukocyte recruitment during inflammation occurs across activated systemic vascular endothelium (Ref. 
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The role of stromal-cell-derived chemokines
Tissue-associated chemokine gradients also direct cellular localisation. Chemokines are important molecular signposts, playing an important role in cell exit from the circulation and retention within tissues (Ref. CCR1  CCR2  CCR3  CCR5  CCR6  CXCR1  CXCR2  CXCR3  CCR4  CCR7  CXCR4  CXCR5  CCR8  CCR9  CCR10  CXCR6   CX Lymphocyte migration into secondary lymph nodes and the generation of secondary lymphoid structures is regulated by B-cellactivating chemokine (BCA-1; CXCL13), which acts on CXCR5, and secondary lymphoid tissue chemokine (SLC; CCL21) and EBL-1-ligand chemokine (ELC; CCL19), which both act on CCR7 (Ref. 17) . SLC is expressed by high endothelial venules and attracts CCR7-bearing lymphocytes. SLC and ELC present in the parafollicular area regulate T-cell migration, whereas CXCR5-expressing B cells migrate further to the BCA-1-expressing follicles (Ref. 17) .
Less is known about the molecules that regulate monocyte trafficking, but recent evidence suggests that 'breast and kidney expressed chemokine' (BRAK; CXCL14), produced by a range of stromal tissues, is selectively chemotactic for activated monocytes (Ref. 25) . Prostaglandin-induced activation modulates chemokine responsiveness: as BRAK responsiveness increases, the response to traditional monocyte chemoattractants MCP-1, RANTES and SDF-1 decreases. This mechanism might promote monocyte colocalisation with BRAK-producing stromal cells, providing factors important for monocytic differentiation (Refs 25, 26) .
Combinations of adhesion molecules impart tissue tropism, with additional contributions 
Stromal determinants of inflammatory cell survival and retention at sites of inflammation
The supposition that the selective accumulation of distinct leukocyte subsets at sites of inflammation is a result of endothelial selection at the point of entry has largely been the prevailing paradigm (Ref. 29) . Selection within the tissue, meditated by stromal determinants, has received relatively little attention, despite their welldefined role during lymphocyte development in the BM and thymus. However, in order to persist, an inflammatory infiltrate must result from an imbalance between cell recruitment, proliferation, emigration and death, and the stromal environment plays an important role in this. Resolution of the infiltrate depends on the dominance of factors depleting the infiltrating cell pool over factors increasing the infiltrating cell pool. By contrast, persistence of inflammation occurs when cell recruitment or proliferation is ongoing, and emigration and death are inhibited (Fig. 3) .
After crossing post-capillary venules into the subendothelial compartment, leukocytes encounter a stromal microenvironment that is quite distinct from that found in the vascular compartment. It has emerged in recent years that, while providing the anatomical environment in which the immune response occurs, stromal cells also directly participate in the induction and effector phases of the response -particularly in the switch from the innate to the acquired immune response (Ref. 30) . The T-cell expansion seen after antigenic stimulation is followed by a significant elimination phase, during which cell numbers are restored to a near-basal state. These homeostatic mechanisms depend on the induction 
Clinical examples of inflammation
Although the chronic inflammatory diseases rheumatoid arthritis, Sjögren's syndrome and multiple sclerosis show distinct pathologies and tissue responses, common processes are likely to underlie the inflammatory response since therapeutic intervention with steroids is helpful in many patients with these conditions. As discussed below, each of these diseases requires the recruitment of leukocytes, yet the way in which these infiltrating leukocytes are organised by the differing stromal microenvironment in the three diseases is quite distinct.
Rheumatoid arthritis: chronic inflammation in the joint
Rheumatoid arthritis is a chronic inflammatory disease of unknown aetiology, characterised by a disordered synovial microenvironment in which there is hyperplasia of resident stromal cells and a heavy infiltrate of haematopoietic cells such as T and B cells (Refs 37, 38) . A characteristic feature of the inflammatory infiltrate is the accumulation of lymphocytes into distinctive micro-anatomical structures with architectural features that strongly resemble lymphoid tissue (Ref. 39 ). Lymphocytic activation is supposed to be a primary factor in this process, but it has not been possible to demonstrate direct evidence of a specific target for autoimmune T cells. Indeed, the heterogeneous antigenic reactivities observed in rheumatoid arthritis joints might instead reflect the occurrence of secondary, non-specific sensitisation. A better understanding of the underlying pathological processes in rheumatoid arthritis might be achieved by investigating the hypothesis that cellular recruitment to the joint occurs episodically. Using the concepts detailed above, we can ask (1) why the cells do not simply leave the joint and (2) whether there are local factors that maintain the architecture of an inflammatory infiltrate.
The synovial microenvironment promotes T-cell retention
The accumulation of T cells in the rheumatoid joint has been shown to be due to contributions from the active, chemokine-dependent retention of T cells. It has recently been demonstrated that synovial T cells highly express CXCR4, a receptor not normally found on highly differentiated CD45R0 + T cells in peripheral blood (Refs 40, 41). CXCR4 expression is dependent on factors present in the synovial microenvironment -particularly transforming growth factor β (TGF-β). SDF-1, the ligand for CXCR4, is found at high levels within the synovium and particularly on synovial endothelial cells (Refs 40, 42, 43) . Interestingly, inhibiting the interaction between SDF-1 and CXCR4 in a mouse model of collagen-induced arthritis ameliorated the disease, suggesting that inhibitors of SDF-1-CXCR4 interactions might lead to clinical improvement in rheumatoid arthritis (Ref. 44 ).
The synovial stromal microenvironment prevents T-cell death
As mentioned above, removal of the vast majority of immune cells that were recruited and expanded during the active phase of disease is essential for the successful resolution of an inflammatory The conclusion from present studies can be summarised as follows: the inflammatory infiltrate in rheumatoid arthritis appears to persist as a direct result of sustained recruitment, inappropriate retention and enhanced survival of cells, a process mediated by the abnormal expression of stromal factors associated with the local microenvironment (Switch 2, Fig. 1; Fig. 3 ). Importantly, these studies have suggested that similar molecular mechanisms might be responsible for lymphoid development during embryogenesis and the formation of lymphoid aggregates in chronic inflammation, particularly with regard to the production of chemokines. In Sjögren's syndrome, recent studies have now shown that the accumulation of lymphocytes in GC-like structures within inflamed tissue is also associated with the ectopic expression of the lymphoid-tissue homing chemokines BCA-1 and SDF-1 (Ref. 58). Inflamed glands (but not control tissue) from patients with Sjögren's syndrome expressed very high levels of BCA-1 on endothelial-like structures found abundantly throughout the inflamed tissue. In contrast to the situation in rheumatoid arthritis, SDF-1 was expressed on ductal epithelial tissue, rather than on fibroblasts and endothelium (Ref. 58) .
Sjögren's syndrome: chronic inflammation in exocrine glands
Taken together, these findings suggest that the inappropriate temporal and spatial expression of chemokines plays an important role in determining the persistence and patterning of lymphoid aggregates within chronically inflamed tissues. They also provide strong support for the hypothesis that the ectopic expression of chemokines is a general feature that drives leukocyte accumulation in chronic inflammatory rheumatic diseases (Fig. 4) . The origin of these cells has been the subject of some dispute: for a long time, the CNS was considered an immunologically privileged site, but research performed over the past decade has indicated that this notion no longer holds true (Ref. 62) . Evidence of inflammatory cell trafficking from the periphery into the CNS in humans has been elegantly demonstrated in human studies performed on allogeneic BM transplantation (IFN-γ) , are released by infiltrating haematopoietic cells, and this leads to the production of inflammatory chemokines (including CXCLs 2-5, CXCLs 1-11 and CX 3 CL1) by the resident stromal cells such as fibroblasts, endothelial and epithelial cells. Constitutive chemokines such as CCL19, CCL21, CXCL12 and CXCL13 are not expressed during a normal, resolving inflammatory response. However, the inappropriate temporal and spatial production of constitutive chemokines by stromal cells is an intriguing feature of chronic persistent inflammatory microenvironments. Indeed, ectopic production of stromal-cell-derived factor 1 (SDF-1) and B-cellactivating chemokine (BCA-1) and their receptors CXCR4 and CXCR5 has been seen in the rheumatoid arthritis synovium and Sjögren's syndrome salivary gland. These chemokines have been demonstrated to be important in the formation of lymphoid tissue (Ref. 97) . If the basal production of constitutive chemokines during inflammation is not tightly regulated, this might lead to the superimposition of lymphoid-like structures within inflamed tissue (fig004cbb). 
Why does inflammation persist
The CNS in inflammatory conditions promotes cellular retention
Little is known about the specific role of chemokines in cellular migration across the blood-brain barrier, and interpretation of observational data is therefore difficult. 
Prevention of T-cell death in the CNS?
Animal models of inflammatory disease in the CNS clearly demonstrate that apoptosis is an important factor in the resolution of the inflammatory infiltrate (Ref. 70) . Despite this, lymphocyte apoptosis is not a prominent feature in multiple sclerosis lesions ( Refs 70, 71) . As lymphocytes persist in CNS infiltrates, it is likely that local factors antagonise apoptotic processes; however, the identity of such factors remains the subject of speculation. Osteopontin [also known as early T lymphocyte activation 1 (Eta-1)] has emerged as a likely important player in multiple sclerosis. This protein has multiple roles in the maintenance of tissue homeostasis during inflammatory processes, including macrophage recruitment and differentiation, inhibition of lymphocyte apoptosis and modulation of cytokine responses (Ref. 72) . Two recent studies have demonstrated that osteopontin is present in the CNS lesions in multiple sclerosis and experimental autoimmune encephalomyelitis, and plays an important role in sustaining autoimmune destruction (Refs 73, 74) . In view of the many physiological roles for this agent, the mechanism of action remains speculative. It is tempting to consider that the established antiapoptotic actions of osteopontin also act to modulate lymphocyte survival in the CNS.
Research in progress and outstanding questions
Some common themes clearly emerge from these studies. 
Clinical implications
Large numbers of inflammatory mediators have now been identified, and many are attractive candidates for therapeutic manipulation in the treatment of chronic inflammatory diseases. Unfortunately, choosing which specific agent to target is difficult, as the dynamic environment makes it difficult to identify a specific hierarchy. It is easy to antagonise a specific cytokine or chemokine in vitro, when the assay read-out is yet another biological mediator. It is altogether more difficult to design an antagonist that produces predictable biological effects in complex microenvironments in vivo.
Changing the viewpoint and identifying specific architectural features in diseased tissues might be a more productive approach. The presence of lymphoid aggregates in the rheumatoid synovium with architectural features that closely mimic secondary lymphoid tissues implies that therapies should be designed to counteract the formation of such structures. This approach provides an attractive functional explanation for the success of anti-TNF therapy in rheumatoid arthritis, since it has recently been demonstrated that TNF family members are essential for lymph-node development (Refs 55, 84, 85). Anti-TNF therapy would therefore be expected to modulate the microenvironmental processes leading to lymphoid aggregate formation in the synovium.
It is unlikely that anti-TNF therapy will be useful for all chronic inflammatory conditions. For example, multiple sclerosis forms an interesting therapeutic contrast to rheumatoid arthritis in that several attempts to treat multiple sclerosis by TNF-α blockade worsened disease rather than improved it (Refs 86, 87). The reason for this is unknown, as prior human and animal studies had suggested that TNF was an important proinflammatory mediator in multiple sclerosis (Refs 88, 89) . The discrepancy might be explained by the important role of TNF-α in nitric oxide (NO) production, and the appreciation that NO inhibits the proliferation of CNS T cells (Ref. 90 ). Inhibition of TNF-α would therefore be proinflammatory in the CNS. By contrast, although IFN-β is a licensed immunomodulator in multiple sclerosis, elucidating its mechanism of action has proved difficult because the agent modulates a large number of genes that are potentially relevant to multiple sclerosis (Refs 91, 92) . IFN-β certainly increases the number of IFN-γ-secreting cells and IFN-γ is an NO inducer, thus providing a potential microenvironmental explanation for the effect (Refs 93, 94) .
These examples highlight how the interplay of complex microenvironmental controls found in tissues can account for apparently contradictory results during clinical trials. Further definition of the hierarchical structures controlling tissue homoeostasis in health and disease will provide numerous exciting avenues for the development of therapies to control chronic inflammatory conditions. 
Why does inflammation persist
